Harrow Partners with Leading Healthcare Market Access Technology Platforms
January 03 2024 - 7:00AM
Business Wire
Agreements Support the Upcoming Launch of
VEVYE®
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical
company, today announced that it has partnered with three leading
healthcare technology platforms to expand U.S. availability of
VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented,
non‑preserved, twice-daily (BID) dosed, ophthalmic solution
prescription drug based on a “water-free” semifluorinated alkane
(SFA) eyedrop technology. VEVYE, uniquely dispensed in a 10
microliter drop, is the first and only cyclosporine-based product
indicated for treating both signs and symptoms of dry eye disease
(DED).
Harrow’s three market access partnerships for VEVYE include:
- PhilRx is an innovative patient access platform that
provides end-to-end visibility into the entire prescription life
cycle, starting when the eyecare professional (ECP) writes a VEVYE
prescription electronically to PhilRx directly from their
electronic health record (EHR). Using the PhilRx platform
simplifies the prior authorization process (PA) for physicians by
providing one-click submission of PAs, streamlining the insurance
coverage process for patients, and increasing the chances of
insurance reimbursement. PhilRx offers a variety of patient
benefits, including best price, fast free shipping, text refill
reminders, and best‑in-class customer service.
- Apollo Care is a comprehensive program designed to
establish and manage copay program deployment, optimizing patient
access and affordability of VEVYE.
- PARx Solutions is a web-based technology stack that
helps prescribers – free of charge – overcome cumbersome,
frustrating, and time-consuming challenges resulting from prior
authorizations, thus ensuring that patients get the medication
prescribed.
In commenting on the announcement, Mark L. Baum, Chairman and
Chief Executive Officer of Harrow, said, “Harrow was founded on a
commitment to patient access. Our 360-degree approach to market
access for VEVYE, including these new partnerships with PhilRx,
Apollo Care, and PARx, is designed to ensure that all patients who
can benefit from VEVYE and who are prescribed VEVYE – can get
VEVYE.
“We believe VEVYE represents an important new prescription
choice in the U.S. dry eye disease market, and we are excited to
streamline the prior authorization process, guiding patients
through their insurance coverage and ensuring competitive pricing –
with minimum hassle. Harrow’s VEVYE market access program perfectly
aligns with our commitment to providing physicians and their
patients with innovative and affordable ophthalmic pharmaceutical
products and the Harrow team eagerly anticipates the availability
of VEVYE – next week.”
For more information about VEVYE, please visit vevye.com.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical
company engaged in the discovery, development, and
commercialization of innovative ophthalmic pharmaceutical products
for the U.S. market. Harrow helps U.S. eyecare professionals
preserve the gift of sight by making its comprehensive portfolio of
prescription and non-prescription pharmaceutical products
accessible and affordable to millions of Americans each year. For
more information about Harrow, please visit harrow.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties which may
cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include, among others, risks related to: liquidity or
results of operations; our ability to successfully implement our
business plan, develop and commercialize our products, product
candidates and proprietary formulations in a timely manner or at
all, identify and acquire additional products, manage our pharmacy
operations, service our debt, obtain financing necessary to operate
our business, recruit and retain qualified personnel, manage any
growth we may experience and successfully realize the benefits of
our previous acquisitions and any other acquisitions and
collaborative arrangements we may pursue; competition from
pharmaceutical companies, outsourcing facilities and pharmacies;
general economic and business conditions, including inflation and
supply chain challenges; regulatory and legal risks and
uncertainties related to our pharmacy operations and the pharmacy
and pharmaceutical business in general; physician interest in and
market acceptance of our current and any future formulations and
compounding pharmacies generally. These and additional risks and
uncertainties are more fully described in Harrow’s filings with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K and its Quarterly Reports on Form 10-Q. Such documents
may be read free of charge on the SEC's web site at sec.gov. Undue
reliance should not be placed on forward‑looking statements, which
speak only as of the date they are made. Except as required by law,
Harrow undertakes no obligation to update any forward-looking
statements to reflect new information, events, or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
About VEVYE® (cyclosporine ophthalmic solution) 0.1%
VEVYE (cyclosporine ophthalmic solution) 0.1%, non-preserved,
for topical ophthalmic use.
INDICATIONS AND USAGE
VEVYE is indicated for the treatment of the signs and symptoms
of dry eye disease.
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
Potential for Eye Injury and Contamination. To avoid the
potential for eye injury and/or contamination, patients should not
touch the bottle tip to the eye or other surfaces.
Use with Contact Lenses. VEVYE should not be administered while
wearing contact lenses. If contact lenses are worn, they should be
removed prior to administration of the solution. Lenses may be
reinserted 15 minutes following administration of VEVYE ophthalmic
solution.
ADVERSE REACTIONS
Clinical Trials Experience. Because clinical trials are
conducted under widely varying conditions, adverse reaction rates
observed in the clinical trials of a drug cannot be directly
compared to rates in the clinical trials of another drug and may
not reflect the rates observed in practice. In clinical trials with
738 subjects receiving at least 1 dose of VEVYE, the most common
adverse reactions were instillation site reactions (8%) and
temporary decreases in visual acuity (3%).
USE IN SPECIAL POPULATIONS
Pregnancy. There are no adequate and well-controlled studies of
VEVYE administration in pregnant women to inform a drug-associated
risk.
Lactation. Caution should be exercised when VEVYE is
administered to a nursing woman.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240103973471/en/
Investors Jamie Webb
Director of Communications and Investor Relations
jwebb@harrowinc.com 615-733-4737
Media Deb Holliday Holliday
Communications, Inc. deb@hollidaycommunications.net
412-877-4519
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Apr 2024 to May 2024
Harrow (NASDAQ:HROW)
Historical Stock Chart
From May 2023 to May 2024